Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial Janet MartinStephen M. StribblingC. J. Springer ORIGINAL ARTICLE Pages: 189 - 201
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease Denis J. MorganJohn S. HillMichael D. Green ORIGINAL ARTICLE Pages: 202 - 208
Human tumor models in the severe combined immune deficient (scid) mouse Gillian D. Paine-MurrietaCharles W. TaylorEvan M. Hersh ORIGINAL ARTICLE Pages: 209 - 214
Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics Ganaganur K. RekhaN. E. Sladek ORIGINAL ARTICLE Pages: 215 - 224
Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma Mark M. ZalupskiPhilip A. PhilipAnthony F. Shields ORIGINAL ARTICLE Pages: 225 - 227
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents Dan L. SackettParaskevi GiannakakouAntonio Fojo ORIGINAL ARTICLE Pages: 228 - 232
Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer Keizo SugimachiYoshihiko MaeharaMasao Tomita ORIGINAL ARTICLE Pages: 233 - 238
Antiestrogenic activities of alternate-substituted polychlorinated dibenzofurans in MCF-7 human breast cancer cells Gulan SunS. Safe ORIGINAL ARTICLE Pages: 239 - 244
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration Zhirong ZhanStefania ScalaT. Fojo ORIGINAL ARTICLE Pages: 245 - 250
Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248) Kathleen W. MosureArris J. HendersonJ. O. Knipe ORIGINAL ARTICLE Pages: 251 - 258
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice Clinton F. StewartWilliam C. ZamboniPeter J. Houghton ORIGINAL ARTICLE Pages: 259 - 265
Effect of single and multiple administration of an O 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model Stephen R. WedgeJulia K. PorteousE. S. Newlands ORIGINAL ARTICLE Pages: 266 - 272
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis J. BellmuntN. EresJ. Baselga CLINICAL TRIAL REPORT Pages: 273 - 276